About EDGAR Online | Login
 
The following is an excerpt from a S-1 SEC Filing, filed by XCEL PHARMACEUTICALS INC on 8/22/2003.
Next Section Next Section Previous Section Previous Section
XCEL PHARMACEUTICALS INC - S-1 - 20030822 - CAPITALIZATION

CAPITALIZATION

 

The following table sets forth our capitalization as of June 30, 2003:

 

    on an actual basis; and

 

    on a pro forma as adjusted basis to give effect to:

 

    the conversion of all outstanding shares of our convertible preferred stock into 18,750,000 shares of common stock upon the closing of this offering;

 

    the sale of              shares of common stock by us in the offering at an assumed initial public offering price of $             per share, which is the midpoint of our expected public offering range for our common stock in this offering;

 

    deducting the underwriting discounts and commissions and estimated offering expenses; and

 

    the filing of our amended and restated certificate of incorporation upon the closing of this offering increasing our authorized shares of common stock to 100,000,000 and changing our authorized shares of preferred stock to 5,000,000.

 

You should read this table together with “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” our financial statements and the related notes appearing elsewhere in this prospectus.

 

       As of June 30, 2003

 
       Actual

     Pro Forma
As Adjusted


 
       (in thousands, except share data)  

Cash and cash equivalents

     $ 29,694      $    
      


  


Long-term debt, including current portion

     $ 62,000      $    
      


  


Stockholders’ equity:

                   

Convertible preferred stock; $0.0001 par value; 52,200,000 shares authorized actual and no shares authorized pro forma as adjusted; 18,750,000 shares issued and outstanding actual and no shares issued and outstanding pro forma as adjusted

       3         

Preferred stock; $0.0001 par value; no shares authorized, issued or outstanding actual; 5,000,000 shares authorized and no shares issued or outstanding pro forma as adjusted

               

Common stock; $0.0001 par value; 62,200,000 shares authorized actual; 100,000,000 shares authorized pro forma as adjusted; 4,778,980 shares issued and outstanding actual and                      shares issued and outstanding pro forma as adjusted

       1           

Additional paid-in capital

       101,748           

Deferred stock-based compensation

       (851 )      (851 )

Retained earnings

       23,076        23,076  
      


  


Total stockholders’ equity

       123,977           
      


  


Total capitalization

     $ 185,977      $    
      


  


 

The actual and pro forma as adjusted information set forth in the table excludes:

 

    1,039,192 shares of our common stock issuable upon exercise of options outstanding under our 2001 Stock Plan as of June 30, 2003 at a weighted average exercise price of $4.86 per share; and

 

    2,000,000 additional shares to be available for future issuances under our 2003 Stock Incentive Plan to be adopted in connection with this offering, including 181,828 additional shares of our common stock reserved for grant as of June 30, 2003 under our 2001 Stock Plan.

 

From July 1, 2003 through August 22, 2003, we granted options to purchase 92,181 shares of our common stock at an exercise price of $5.00 per share.

 

19


Table of Contents